Michela Garofalo

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint MicroRNAs as anti-cancer therapy
    Michela Garofalo
    The Ohio State University, 992, Biomedical Research Tower, 460 W 12th Avenue, Columbus, OH 43210
    Curr Pharm Des 20:5328-35. 2014
  2. pmc MicroRNAs in cancer
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 email
    Annu Rev Pathol 9:287-314. 2014
  3. pmc MicroRNAs as therapeutic targets in chemoresistance
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA Electronic address
    Drug Resist Updat 16:47-59. 2013
  4. doi request reprint microRNAs: Master regulators as potential therapeutics in cancer
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Annu Rev Pharmacol Toxicol 51:25-43. 2011
  5. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
  6. pmc EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Nat Med 18:74-82. 2011
  7. pmc Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, School of Medicine, The Ohio State University, Columbus, Ohio, United States of America
    PLoS Genet 9:e1003311. 2013
  8. pmc MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e67581. 2013
  9. pmc MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC
    Pooja Joshi
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210
    Proc Natl Acad Sci U S A 112:8650-5. 2015
  10. pmc Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
    Mario Acunzo
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 110:8573-8. 2013

Collaborators

Detail Information

Publications21

  1. ncbi request reprint MicroRNAs as anti-cancer therapy
    Michela Garofalo
    The Ohio State University, 992, Biomedical Research Tower, 460 W 12th Avenue, Columbus, OH 43210
    Curr Pharm Des 20:5328-35. 2014
    ..Those include viral or non-viral approaches of miRNA replacement therapy in the case of tumor-suppressing miRNAs and strategies for the inhibition of oncogenic miRNAs. ..
  2. pmc MicroRNAs in cancer
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 email
    Annu Rev Pathol 9:287-314. 2014
    ....
  3. pmc MicroRNAs as therapeutic targets in chemoresistance
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA Electronic address
    Drug Resist Updat 16:47-59. 2013
    ..Here, we will discuss the involvement of microRNAs in chemotherapy resistance and focus on recent advancements in the development and delivery of miRNA-based cancer therapeutics. ..
  4. doi request reprint microRNAs: Master regulators as potential therapeutics in cancer
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Annu Rev Pharmacol Toxicol 51:25-43. 2011
    ....
  5. pmc Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
    Flavia Pichiorri
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Cancer Cell 18:367-81. 2010
    ..The results suggest that these miRNAs are positive regulators of p53 and that their downregulation plays a key role in MM development...
  6. pmc EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Nat Med 18:74-82. 2011
    ..These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs...
  7. pmc Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, School of Medicine, The Ohio State University, Columbus, Ohio, United States of America
    PLoS Genet 9:e1003311. 2013
    ..Importantly, we demonstrated that the miR-191/425 cluster, by reducing the expression of an extensive network of genes, has a fundamental impact on cancer initiation and progression of breast cancer cells...
  8. pmc MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e67581. 2013
    ..Finally, miR-34a/c overexpression or downregulation of PDGFR-α/β by siRNAs, strongly augmented the response to TNF-related apoptosis inducing ligand (TRAIL) while reducing migratory and invasive capacity of NSCLC cells...
  9. pmc MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC
    Pooja Joshi
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210
    Proc Natl Acad Sci U S A 112:8650-5. 2015
    ..These findings suggest that miR-148a acts as a tumor suppressor and might have therapeutic application in the treatment of NSCLC...
  10. pmc Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
    Mario Acunzo
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 110:8573-8. 2013
    ..In addition, we identify both direct and indirect mechanisms by which miR-27a can regulate both MET and EGFR. Thus, we propose a mechanism for MET and EGFR axis regulation that may lead to the development of therapeutics in lung cancer...
  11. pmc A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer
    Young Jun Jeon
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210
    Proc Natl Acad Sci U S A 112:E3355-64. 2015
    ..Finally, we prove that combinatory treatment of NF-κB inhibitors and TRAIL is able to revert resistance and reduce tumor growth, with important consequences for the clinical practice. ..
  12. pmc A mathematical model for microRNA in lung cancer
    Hye Won Kang
    Mathematical Biosciences Institute, Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 8:e53663. 2013
    ..However, very little is presently known about factors that regulate let-7. It is quite possible that when such regulating factors become known and integrated into our model, they will further support our mathematical model...
  13. pmc MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, 460 West, 12th Ave, Columbus, OH 43210, USA
    J Natl Cancer Inst 102:706-21. 2010
    ..Because microRNAs (miRNAs) modulate gene expression, we hypothesized that they may have a role in ER-negative tumor formation...
  14. pmc Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri
    Virginia A Folcik
    1 The Ohio State University OSU at Marion, Marion, OH, USA 2 OSU Computer Science and Engineering, Marion, OH, USA 3 OSU Innovation Group for the Study of Complexity in Human, Natural, and Engineered Systems, Marion, OH, USA
    Mod Pathol 27:851-62. 2014
    ..Thus, treatment directed against viral proliferation and/or viral-associated proteins may halt disease progression. Further, demonstration of the viral nucleic acids or proteins may help diagnose the disease. ..
  15. pmc Non-coding RNAs and cancer
    Federica Calore
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Int J Mol Sci 14:17085-110. 2013
    ..In this review we will discuss the recent remarkable advancement in the understanding the biological functions of human ncRNAs in cancer, the mechanisms of expression and the therapeutic potential. ..
  16. pmc miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 16:498-509. 2009
    ..Finally, we demonstrate that the MET oncogene is involved in miR-221&222 activation through the c-Jun transcription factor...
  17. pmc Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples
    Gerard J Nuovo
    The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Mod Pathol 25:1333-44. 2012
    ..A rate-limiting factor of reovirus-induced cancer cell death is productive viral infection that operates via the marked reduction of microRNA-let-7d and concomitant elevated caspase-3 expression...
  18. doi request reprint Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease
    Louisa Mezache
    Phylogeny Inc OSU Comprehensive Cancer Center, Columbus, OH
    Appl Immunohistochem Mol Morphol 23:615-23. 2015
    ..This, in turn, could lead to the accumulation of key Alzheimer proteins such as hyperphosphorylated tau that ultimately prevent normal neuronal function and lead to disease symptomatology. ..
  19. pmc Role of microRNAs in maintaining cancer stem cells
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK Electronic address
    Adv Drug Deliv Rev 81:53-61. 2015
    ..This review focuses on the last advances on the role of microRNAs in the regulation of stem cell properties and cancer stem cells in different tumors. ..
  20. doi request reprint MicroRNAs in diseases and drug response
    Michela Garofalo
    Department of Molecular, Virology, Immunology and Medical Genetics, Biomedical Research Tower 460W, 12th Avenue, Room 1060, Columbus, OH 43210, USA
    Curr Opin Pharmacol 8:661-7. 2008
    ..An understanding of how microRNAs influence the body's response to certain drugs and how these affect the expression of microRNAs, will be of key importance in developing drugs with greater safety and efficacy...
  21. pmc Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
    Ramiro Garzon
    Departments of Medicine and Molecular Virology and Human Genetics, Comprehensive Cancer Center, and College of Pharmacology, Ohio State University, Columbus, OH 43221, USA
    Proc Natl Acad Sci U S A 105:3945-50. 2008
    ..Moreover, we found that miR-155 was strongly but independently associated with FLT3-ITD mutations...